Literature DB >> 11988637

Electron transport chain defects in heart failure.

Jordi Casademont1, Oscar Miró.   

Abstract

In recent years, the possibility that disorders of cardiac metabolism play a role in the mechanisms that lead to ventricular dilatation and dysfunction in heart failure has attracted much attention. Electron transport chain is constituted by a series of multimeric protein complexes, located in the inner mitochondrial membranes, whose genes are distributed over both nuclear and mitochondrial DNA. Its normal function is essential to provide the energy for cardiac function. Many studies have described abnormalities in mitochondrial DNA genes encoding for electron transport chain (ETC) in dilated cardiomyopathies. In some cases, heart failure is one more or less relevant symptom among other multisystem manifestations characteristic of mitochondrial encephalomyopathies, being heart failure imputable to a primary mitochondrial disease. In the case of idiopathic dilated cardiomyopathies (IDC), many mitochondrial abnormalities have also been described using hystological, biochemical or molecular studies. The importance of such findings is under debate. The great variability in the mitochondrial abnormalities described has prompted the proposal that mitochondrial dysfunction could be a secondary phenomenon in IDC, and not a primary one. Among other possible explanations for such findings, the presence of an increased oxidative damage due to a free radical excess has been postulated. In this setting, the dysfunction of ETC could be a consequence, but also a cause of the presence of an increased free radical damage. Independently of its origin, ETC dysfunction may contribute to the persistence and worsening of heart failure. If this hypothesis, still to be proven, was certain, the modulation of cardiac metabolism could be an interesting approach to treat IDC. The precise mechanisms that lead to ventricular dilatation and dysfunction in heart failure are still nowadays poorly understood. Circumstances such as cytotoxic insults, viral infections, immune abnormalities, contractile protein defects, ischemic factors and familial conditions have been thoroughly investigated [1]. It is possible that several mechanisms combine to produce the clinical syndrome of heart failure. In recent years the possibility that disorders of energy metabolism, either isolated or in combination with the other aforementioned factors, may play a role in the development of heart failure in susceptible patients has attracted much attention. The present paper reviews the current knowledge on mitochondrial function in the failing myocardium. We restrain our discussion to heart failure where an impaired inotropic state leads to a weakened systolic contraction (i.e. the so-called systolic heart failure). Idiopathic dilated cardiomyopathy (IDC) is the prototype of the conditions under discussion. Other circumstances where a defect in myocardial contraction is due to a chronic excessive work load (i.e., hypertension, valvular or congenital heart diseases), and states in which the principal abnormality involves impaired relaxation of the ventricle (i.e. diastolic heart failure), as well as mitochondrial defects outside the electron transport chain (i.e., defects in Krebs cycle or beta-oxidation of fatty acids) are only approached circumstantially.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988637     DOI: 10.1023/a:1015372407647

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  86 in total

1.  A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study.

Authors:  R LUFT; D IKKOS; G PALMIERI; L ERNSTER; B AFZELIUS
Journal:  J Clin Invest       Date:  1962-09       Impact factor: 14.808

2.  Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain.

Authors:  S Pitkanen; F Merante; D R McLeod; D Applegarth; T Tong; B H Robinson
Journal:  Pediatr Res       Date:  1996-03       Impact factor: 3.756

Review 3.  Idiopathic dilated cardiomyopathy.

Authors:  G W Dec; V Fuster
Journal:  N Engl J Med       Date:  1994-12-08       Impact factor: 91.245

4.  Maternally inherited myopathy and cardiomyopathy: association with mutation in mitochondrial DNA tRNA(Leu)(UUR).

Authors:  M Zeviani; C Gellera; C Antozzi; M Rimoldi; L Morandi; F Villani; V Tiranti; S DiDonato
Journal:  Lancet       Date:  1991-07-20       Impact factor: 79.321

Review 5.  Mitochondrial diseases in man and mouse.

Authors:  D C Wallace
Journal:  Science       Date:  1999-03-05       Impact factor: 47.728

6.  Absence of relationship between the level of electron transport chain activities and aging in human skeletal muscle.

Authors:  A Barrientos; J Casademont; A Rötig; O Miró; A Urbano-Márquez; P Rustin; F Cardellach
Journal:  Biochem Biophys Res Commun       Date:  1996-12-13       Impact factor: 3.575

7.  Hypoxemia is associated with mitochondrial DNA damage and gene induction. Implications for cardiac disease.

Authors:  M Corral-Debrinski; G Stepien; J M Shoffner; M T Lott; K Kanter; D C Wallace
Journal:  JAMA       Date:  1991-10-02       Impact factor: 56.272

8.  Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy.

Authors:  E Arbustini; M Diegoli; R Fasani; M Grasso; P Morbini; N Banchieri; O Bellini; B Dal Bello; A Pilotto; G Magrini; C Campana; P Fortina; A Gavazzi; J Narula; M Viganò
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with maternally inherited cardiomyopathy.

Authors:  G Silvestri; F M Santorelli; S Shanske; C B Whitley; L A Schimmenti; S A Smith; S DiMauro
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

10.  Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency.

Authors:  V Tiranti; K Hoertnagel; R Carrozzo; C Galimberti; M Munaro; M Granatiero; L Zelante; P Gasparini; R Marzella; M Rocchi; M P Bayona-Bafaluy; J A Enriquez; G Uziel; E Bertini; C Dionisi-Vici; B Franco; T Meitinger; M Zeviani
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

View more
  34 in total

Review 1.  Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury.

Authors:  Nina Kaludercic; Andrea Carpi; Roberta Menabò; Fabio Di Lisa; Nazareno Paolocci
Journal:  Biochim Biophys Acta       Date:  2010-09-24

2.  Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress.

Authors:  Dao-Fu Dai; Edward J Hsieh; Yonggang Liu; Tony Chen; Richard P Beyer; Michael T Chin; Michael J MacCoss; Peter S Rabinovitch
Journal:  Cardiovasc Res       Date:  2011-10-19       Impact factor: 10.787

Review 3.  Regulation of mitochondrial ATP synthase in cardiac pathophysiology.

Authors:  Qinqiang Long; Kevin Yang; Qinglin Yang
Journal:  Am J Cardiovasc Dis       Date:  2015-03-20

Review 4.  Metabolic enzymes dysregulation in heart failure: the prospective therapy.

Authors:  Priyanka Parihar; Mordhwaj Singh Parihar
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

5.  Mechanistic studies on ketamine-induced mitochondrial toxicity in zebrafish embryos.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  Neurotoxicol Teratol       Date:  2017-12-07       Impact factor: 3.763

Review 6.  Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective.

Authors:  Andrew A Wolff; Heschi H Rotmensch; William C Stanley; Roberto Ferrari
Journal:  Heart Fail Rev       Date:  2002-04       Impact factor: 4.214

7.  Divergent mitochondrial biogenesis responses in human cardiomyopathy.

Authors:  Preeti Ahuja; Jonathan Wanagat; Zhihua Wang; Yibin Wang; David A Liem; Peipei Ping; Igor A Antoshechkin; Kenneth B Margulies; W Robb Maclellan
Journal:  Circulation       Date:  2013-04-15       Impact factor: 29.690

8.  Renin-angiotensin system inhibitors protect against age-related changes in rat liver mitochondrial DNA content and gene expression.

Authors:  Elena M V de Cavanagh; Idhaliz Flores; Marcelo Ferder; Felipe Inserra; León Ferder
Journal:  Exp Gerontol       Date:  2008-08-15       Impact factor: 4.032

Review 9.  Alterations in mitochondrial function in cardiac hypertrophy and heart failure.

Authors:  Moritz Osterholt; T Dung Nguyen; Michael Schwarzer; Torsten Doenst
Journal:  Heart Fail Rev       Date:  2013-09       Impact factor: 4.214

10.  Substrate-specific impairment of mitochondrial respiration in permeabilized fibers from patients with coronary heart disease versus valvular disease.

Authors:  Oana Duicu; Călin Juşcă; Lucian Falniţă; Silvia Mirică; Daniela Maximov; Ovidiu Firă-Mladinescu; Danina Muntean
Journal:  Mol Cell Biochem       Date:  2013-04-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.